ACADIA Pharmaceuticals Inc. Share Price Today: Live Updates & Key Insights

ACADIA Pharmaceuticals Inc. share price today is $20.7, up 0.1%. The stock opened at $20.615 against the previous close of $20.72, with an intraday high of $21.025 and low of $20.615.

ACADIA Pharmaceuticals Inc. Share Price Chart

ACADIA Pharmaceuticals Inc.

us-stock
To Invest in {{usstockname}}
us-stock

ACADIA Pharmaceuticals Inc. Share Price Performance

$20.7 0.001(0.1%) ACAD at 23 Mar 2026 11:52 AM Biotechnology
Lowest Today 20.615
Highest Today 21.025
Today’s Open 20.615
Prev. Close 20.72
52 Week High 28.35
52 Week Low 13.40
Day’s Range: Low 20.615 High 21.025
52-Week Range: Low 13.40 High 28.35
1 day return -
1 Week return -3.13
1 month return -16.28
3 month return -26.15
6 month return -15.49
1 year return +20.32
3 year return +12.06
5 year return -23.25
10 year return -

ACADIA Pharmaceuticals Inc. Institutional Holdings

Baker Bros Advisors LP 25.16

BlackRock Inc 11.89

Vanguard Group Inc 8.89

iShares Core S&P Small-Cap ETF 4.45

State Street Corp 4.26

RTW INVESTMENTS, LLC 4.19

Vanguard Total Stock Mkt Idx Inv 2.35

State Street® SPDR® S&P® Biotech ETF 1.95

Geode Capital Management, LLC 1.90

First Trust NYSE Arca Biotech ETF 1.78

iShares Russell 2000 ETF 1.78

Dimensional Fund Advisors, Inc. 1.71

Vanguard Small Cap Index 1.69

Palo Alto Investors, LLC 1.45

First Trust Advisors L.P. 1.33

The Goldman Sachs Group Inc 1.23

BRAIDWELL LP 1.19

Vanguard Small Cap Growth Index Inv 0.94

Citigroup Inc 0.92

Fred Alger Management, LLC 0.92

Pictet Asset Manangement SA 0.91

Renaissance Technologies Corp 0.90

Deutsche Bank AG 0.89

NORGES BANK 0.88

Arrowstreet Capital Limited Partnership 0.88

TANG CAPITAL MANAGEMENT LLC 0.88

Point72 Asset Management, L.P. 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.79

iShares Biotechnology ETF 0.73

Fidelity Small Cap Index 0.72

State Street SPDR Port S&P 600 Sm CpETF 0.68

iShares S&P Small-Cap 600 Growth ETF 0.63

iShares Russell 2000 Growth ETF 0.61

Vanguard Tax-Managed Small Cap Adm 0.48

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

SSgA Russell Small Cap Completeness Idx 0.42

MFS New Discovery Value I 0.41

State Street® SPDR® S&P 600™ Sm Cp GrETF 0.39

Vanguard Strategic Equity Inv 0.38

Fidelity Extended Market Index 0.38

ACADIA Pharmaceuticals Inc. Market Status

Strong Buy: 7

Buy: 6

Hold: 6

Sell: 1

Strong Sell: 0

ACADIA Pharmaceuticals Inc. Fundamentals

Market Cap 3536.06 M

PB Ratio 2.881

PE Ratio 9.0174

Enterprise Value 2768.56 M

Total Assets 1564.20 M

Volume 3343584

ACADIA Pharmaceuticals Inc. Company Financials

Annual Revenue FY25:1071505000 1071.5M, FY23:631886000 631.9M, FY22:517235000 517.2M, FY21:484145000 484.1M, FY20:441755000 441.8M

Annual Profit FY25:982507000 982.5M, FY23:605726000 605.7M, FY22:507069000 507.1M, FY21:465004000 465.0M, FY20:421205000 421.2M

Annual Net worth FY25:391000000 391.0M, FY23:-148808000 -148.8M, FY22:-215975000 -216.0M, FY21:-167870000 -167.9M, FY20:-281584000 -281.6M

Quarterly Revenue Q4/2025:283989000 284.0M, Q3/2025:278633000 278.6M, Q2/2025:264566000 264.6M, Q1/2025:244317000 244.3M, Q3/2024:250401000 250.4M

Quarterly Profit Q4/2025:257764000 257.8M, Q3/2025:256986000 257.0M, Q2/2025:243832000 243.8M, Q1/2025:223925000 223.9M, Q3/2024:231544000 231.5M

Quarterly Net worth Q4/2025:273568000 273.6M, Q3/2025:71779000 71.8M, Q2/2025:26666000 26.7M, Q1/2025:18987000 19.0M, Q3/2024:32765000 32.8M

About ACADIA Pharmaceuticals Inc. & investment objective

Company Information ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 796

Industry Biotechnology

CEO Ms. Catherine E. Owen Adams

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ACADIA Pharmaceuticals Inc. FAQs

What is the share price of ACADIA Pharmaceuticals Inc. today?

The current share price of ACADIA Pharmaceuticals Inc. is $20.7.

Can I buy ACADIA Pharmaceuticals Inc. shares in India?

Yes, Indian investors can buy ACADIA Pharmaceuticals Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy ACADIA Pharmaceuticals Inc. shares in India?

You can easily invest in ACADIA Pharmaceuticals Inc. shares from India by:

Can I buy fractional shares of ACADIA Pharmaceuticals Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ACADIA Pharmaceuticals Inc.?

ACADIA Pharmaceuticals Inc. has a market cap of $3536.06 M.

In which sector does ACADIA Pharmaceuticals Inc. belong?

ACADIA Pharmaceuticals Inc. operates in the Biotechnology sector.

What documents are required to invest in ACADIA Pharmaceuticals Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of ACADIA Pharmaceuticals Inc.?

The PE ratio of ACADIA Pharmaceuticals Inc. is 9.02 and the PB ratio is 2.88.